Clinical Trial Update: Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating efficacy, safety, and dose-response of lofexidine for opioid withdrawal, followed by an open-label study, with completed status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Dependence
• Opioid Withdrawal Syndrome

Drugs mentioned

• LOFEXIDINE (LOFEXIDINE)

Snippet

Sponsor: USWM, LLC (dba US WorldMeds) | Conditions: Opioid Dependence, Acute Opioid Withdrawal Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2021-02-04